NOD2 triggers an interleukin-32-dependent human dendritic cell program in leprosy

Nature Medicine

Volumn 18, Issue 4, 2012, Pages 555-563

  Schenk, Mirjam ^a   Krutzik, Stephan R ^a   Sieling, Peter A ^a   Lee, Delphine J ^a,e   Teles, Rosane M B ^a   Ochoa, Maria Teresa ^a   Komisopoulou, Evangelia ^a   Sarno, Euzenir N ^b   Rea, Thomas H ^c   Graeber, Thomas G ^a   Kim, Soohyun ^d   Cheng, Genhong ^a   Modlin, Robert L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Konkuk University   (South Korea)

^e JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CD1B ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR ANTIBODY; INTERLEUKIN 32; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MURAMYL DIPEPTIDE; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING KINETICS; CELL DIFFERENTIATION; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE COURSE; LEPROSY; LEUKOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

ANTIGENS, CD; ANTIGENS, CD11B; CELL DIFFERENTIATION; CYTOKINES; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKINS; LEPROSY; LIGANDS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; NOD2 SIGNALING ADAPTOR PROTEIN; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; RNA, MESSENGER;

EID: 84862805230     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2650     Document Type: Article

References (55)

1. Medzhitov, R., Preston-Hurlburt, P. & Janeway, C.A.J. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388, 394-397 (1997).
2. Brightbill, H.D. et al. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 285, 732-736 (1999).
3. Ferwerda, G. et al. NOD2 and Toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog. 1, 279-285 (2005).
4. Bloom, B.R. Learning from leprosy: A perspective on immunology and the third world. J. Immunol. 137, i-x (1986).
5. Ridley, D.S. & Jopling, W.H. Classification of leprosy according to immunity. A five-group system. Int. J. Lepr. Other Mycobact. Dis. 34, 255-273 (1966).
6. Yamamura, M. et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 254, 277-279 (1991).
7. Salgame, P. et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 254, 279-282 (1991).
8. Sieling, P.A. et al. CD1 expression by dendritic cells in human leprosy lesions: Correlation with effective host immunity. J. Immunol. 162, 1851-1858 (1999).
9. Takeuchi, O. et al. Role of TLR1 in mediating immune response to microbial lipoproteins. J. Immunol. 169, 10-14 (2002).
10. Krutzik, S.R. et al. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat. Med. 9, 525-532 (2003).
11. Kang, T.J. & Chae, G.T. Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. FEMS Immunol. Med. Microbiol. 31, 53-58 (2001).
12. Kang, T.J., Lee, S.B. & Chae, G.T. A polymorphism in the Toll-like receptor 2 is associated with IL-12 production from monocyte in lepromatous leprosy. Cytokine 20, 56-62 (2002).
13. Bochud, P.Y., Hawn, T.R. & Aderem, A. Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. J. Immunol. 170, 3451-3454 (2003).
14. Schröder, N.W. et al. High frequency of polymorphism Arg753Gln of the Toll-like receptor-2 gene detected by a novel allele-specific PCR. J. Mol. Med. 81, 368-372 (2003).
15. Kang, T.J., Yeum, C.E., Kim, B.C., You, E.Y. & Chae, G.T. Differential production of interleukin-10 and interleukin-12 in mononuclear cells from leprosy patients with a Toll-like receptor 2 mutation. Immunology 112, 674-680 (2004).
16. Malhotra, D., Relhan, V., Reddy, B.S. & Bamezai, R. TLR2 Arg677Trp polymorphism in leprosy: revisited. Hum. Genet. 116, 413-415 (2005).
17. Johnson, C.M. et al. Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J. Immunol. 178, 7520-7524 (2007).
18. Misch, E.A. et al. Human TLR1 deficiency is associated with impaired mycobacterial signaling and protection from leprosy reversal reaction. PLoS Negl. Trop. Dis. 2, e231 (2008).
19. Schuring, R.P. et al. Polymorphism N248S in the human Toll-like receptor 1 gene is related to leprosy and leprosy reactions. J. Infect. Dis. 199, 1816-1819 (2009).
20. Yang, Y. et al. NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2. J. Biol. Chem. 282, 36223-36229 (2007).
21. Girardin, S.E. et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278, 8869-8872 (2003).
22. Zhang, F.R. et al. Genomewide association study of leprosy. N. Engl. J. Med. 361, 2609-2618 (2009).
23. Berrington, W.R. et al. Common polymorphisms in the NOD2 gene region are associated with leprosy and its reactive states. J. Infect. Dis. 201, 1422-1435 (2010).
24. Krutzik, S.R. et al. TLR activation triggers the rapid differentiation of monocytes into macrophages and dendritic cells. Nat. Med. 11, 653-660 (2005).
25. + T cells by targeting MHC class II epitopes to endosomal compartments using human CD1 tail sequences. Immunology 122, 522-531 (2007).
26. Netea, M.G. et al. Interleukin-32 induces the differentiation of monocytes into macrophage-like cells. Proc. Natl. Acad. Sci. USA 105, 3515-3520 (2008).
27. Netea, M.G. et al. Mycobacterium tuberculosis induces interleukin-32 production through a caspase-1/IL-18/interferon-γ-dependent mechanism. PLoS Med. 3, e277 (2006).
28. Bai, X. et al. IL-32 is a host protective cytokine against Mycobacterium tuberculosis in differentiated THP-1 human macrophages. J. Immunol. 184, 3830-3840 (2010).
29. Nold, M.F. et al. Endogenous IL-32 controls cytokine and HIV-1 production. J. Immunol. 181, 557-565 (2008).
30. Li, W. et al. Activation of interleukin-32 pro-inflammatory pathway in response to influenza A virus infection. PLoS ONE 3, e1985 (2008).
31. Joosten, L.A. et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 103, 3298-3303 (2006).
32. Shioya, M. et al. Epithelial overexpression of interleukin-32α in inflammatory bowel disease. Clin. Exp. Immunol. 149, 480-486 (2007).
33. Marcondes, A.M. et al. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. Proc. Natl. Acad. Sci. USA 105, 2865-2870 (2008).
34. Lee, D.J. et al. LILRA2 activation inhibits dendritic cell differentiation and antigen presentation to T cells. J. Immunol. 179, 8128-8136 (2007).
35. Bleharski, J.R. et al. Use of genetic profiling in leprosy to discriminate clinical forms of the disease. Science 301, 1527-1530 (2003).
36. Montoya, D. et al. Divergence of macrophage phagocytic and antimicrobial programs in leprosy. Cell Host Microbe 6, 343-353 (2009).
37. Sieling, P.A. et al. CD1-restricted T cell recognition of microbial lipoglycans. Science 269, 227-230 (1995).
38. Sieling, P.A. et al. Immunosuppressive roles for interleukin-10 and interleukin-4 in human infection: in vitro modulation of T cell responses in leprosy. J. Immunol. 150, 5501-5510 (1993).
39. Krutzik, S.R. et al. IL-15 links TLR2/1-induced macrophage differentiation to the vitamin D-dependent antimicrobial pathway. J. Immunol. 181, 7115-7120 (2008).
40. Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor αa. J. Exp. Med. 179, 1109-1118 (1994).
41. Silva, C.L., Palacios, A., Colston, M.J. & Lowrie, D.B. Mycobacterium leprae 65hsp antigen expressed from a retroviral vector in a macrophage cell line is presented to T cells in association with MHC class II in addition to MHC class I. Microb. Pathog. 12, 27-38 (1992).
42. Modlin, R.L., Hofman, F.M., Taylor, C.R. & Rea, T.H. T lymphocyte subsets in the skin lesions of patients with leprosy. J. Am. Acad. Dermatol. 8, 182-189 (1983).
43. H17-polarizing ability through enhanced IL-12 and IL-6 production. J. Immunol. 186, 6848-6859 (2011).
44. Martinon, F., Mayor, A. & Tschopp, J. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27, 229-265 (2009).
45. Coley, W.B. The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. Am. J. Med. Sci. 105, 487-511 (1893).
46. Morales, A., Eidinger, D. & Bruce, A.W. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J. Urol. 116, 180-183 (1976).
47. Morton, D., Eilber, F.R., Malmgren, R.A. & Wood, W.C. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68, 158-163 (1970).
48. Adam, A., Ciorbaru, R., Ellouz, F., Petit, J.F. & Lederer, E. Adjuvant activity of monomeric bacterial cell wall peptidoglycans. Biochem. Biophys. Res. Commun. 56, 561-567 (1974).
49. Ellouz, F., Adam, A., Ciorbaru, R. & Lederer, E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem. Biophys. Res. Commun. 59, 1317-1325 (1974).
50. Specter, S., Cimprich, R., Friedman, H. & Chedid, L. Stimulation of an enhanced in vitro immune response by a synthetic adjuvant, muramyl dipeptide. J. Immunol. 120, 487-491 (1978).
51. Sugimoto, M., Germain, R.N., Chedid, L. & Benacerraf, B. Enhancement of carrier-specific helper T cell function by the synthetic adjuvant, N-acetyl muramyl-l-alanyl-d-isoglutamine (MDP). J. Immunol. 120, 980-982 (1978).
52. Kleinerman, E.S. et al. Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol. Immunother. 34, 211-220 (1992).
53. Ridley, D.S. Histological classification and the immunological spectrum of leprosy. Bull. World Health Organ. 51, 451-465 (1974).
54. Liu, P.T. et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311, 1770-1773 (2006).
55. Monney, L. et al. TH1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 415, 536-541 (2002).